US12611401B2 - Pfizer Benzodioxol GLP-1R Agonist Combinations for NASH
Summary
USPTO granted patent US12611401B2 to Pfizer Inc. on April 28, 2026. The patent covers combinations of benzodioxol GLP-1R agonists with ACC, DGAT2, KHK, or FXR inhibitors for treating NASH, NAFLD, fatty liver disease, obesity, and type 2 diabetes. The patent includes 11 claims and names 19 inventors across multiple therapeutic compound combinations and treatment methods.
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
USPTO issued patent US12611401B2 to Pfizer Inc. covering new therapeutic combinations for treating NASH, NAFLD, fatty liver, and related metabolic diseases. The patent claims a combination comprising a GLP-1R agonist with an ACC inhibitor, DGAT2 inhibitor, KHK inhibitor, or FXR agonist, along with methods of using these combinations to treat the specified conditions.
Pharmaceutical companies developing GLP-1 receptor-based therapies for liver and metabolic diseases should conduct freedom-to-operate analyses given this patent. The patent provides Pfizer with exclusive rights to the claimed combinations and methods in the United States for the duration of the patent term.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
Grant US12611401B2 Kind: B2 Apr 28, 2026
Assignee
Pfizer Inc.
Inventors
Gary E. Aspnes, Scott W. Bagley, John M. Curto, Matthew Dowling, David James Edmonds, Dilinie Fernando, Mark E. Flanagan, Kentaro Futatsugi, David Andrew Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Shawn M. LaCasse, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David Walter Piotrowski, Roger B. Ruggeri, Kristin Wiglesworth
Abstract
In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
CPC Classifications
A61K 31/438 A61K 31/454 A61K 31/4545 A61K 31/46 A61K 31/496 A61K 31/506 A61K 31/5377 A61P 1/16
Filing Date
2020-05-15
Application No.
17612672
Claims
11
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.